Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Hui-Peng Lee, Stephen S. Opat, John Hrom, David Kliman, Paula Marlton, Peng Liu, Chenmu Du, Amber Lussier, Jun Zhang, Haiyi Guo, Steven P. Treon

Blood (2024) 144 (Supplement 1): 1661.1.

https://doi.org/10.1182/blood-2024-198728

Published: 2024

Journal Articles

Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

Judith Trotman, Katherine Rankin, Ibrahim Tohidi-Esfahani, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G Owen, Veronique LeBlond, Meletios A. Dimopoulos, Peter Smallwood, Heather Allewelt, Wai Y Chan, Radha Prathikanti, Jingjing Schneider, Remus Vezan, Stephen S. Opat

Blood (2024) 144 (Supplement 1): 4412.

https://doi.org/10.1182/blood-2024-200334

Published: 2024

Journal Articles

Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study

Shirley D'Sa, Meletios A. Dimopoulos, Wojciech Jurczak, Paula Marlton, Stephen P. Mulligan, Bjorn E Wahlin, Magdalena Sobieraj-Teague, Andrew W. Roberts, Constantine S. Tam, Jorge J. Castillo, Heather Allewelt, Radha Prathikanti, Wai Y Chan, Tian Tian, Jingjing Schneider, Remus Vezan, Stephen S. Opat

Blood (2024) 144 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2024-199276

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Blood (2024) 144 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2024-204328

Published: 2024

Journal Articles

Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101

Jacob D. Soumerai, Chan Y. Cheah, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, Wei Ding, Haiyi Guo, Constantine S. Tam

Blood (2024) 144 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2024-199175

Published: 2024

Journal Articles

Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study

Constantine S. Tam, Stephen S. Opat, Eileen Grace Merriman, Jan A. Burger, Emma Verner, Paula Marlton, David Gottlieb, Ian W. Flinn, Sumit Madan, Matthew Ku, Radha Prathikanti, Heather Allewelt, Tian Tian, Remus Vezan, Gavin Cull

Blood (2024) 144 (Supplement 1): 3255.

https://doi.org/10.1182/blood-2024-200363

Published: 2024

Journal Articles

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

Alessandra Tedeschi, Chan Yoon Cheah, Stephen S. Opat, Emma Verner, Laura Magnano, Narendranath Epperla, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Mary Ann Anderson

Blood (2023) 142 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2023-178841

Published: 2023

Journal Articles

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ Trial

Blood (2023) 142 (Supplement 1): 735.

https://doi.org/10.1182/blood-2023-178403

Published: 2023

Journal Articles

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Blood (2023) 142 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2023-181541

Published: 2023

Journal Articles

Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

Constantine S. Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Chan Yoon Cheah

Blood (2023) 142 (Supplement 1): 327.

https://doi.org/10.1182/blood-2023-179541

Published: 2023

Journal Articles

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Blood (2023) 142 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2023-173247

Published: 2023

Journal Articles

The Feasibility and Safety of Anticoagulation during Chemotherapy Associated Thrombocytopenia for Thrombotic Complications of Malignancy.

Mark N. Polizzotto, MD, Stephen S. Opat, MD

Blood (2007) 110 (11): 1872.

https://doi.org/10.1182/blood.V110.11.1872.1872

Published: 2007

Journal Articles

Allogeneic Peripheral Blood Stem Cell Transplantation for Hematological Malignancies in Patients with HIV.

Mark N. Polizzotto, MB, BS, Jake Shortt, MB ChB, Merrole F. Cole-Sinclair, MB BS, Stephen S. Opat, MB BS, Andrew Spencer, MB BS, Sharon Avery, MB BS

Blood (2007) 110 (11): 4941.

https://doi.org/10.1182/blood.V110.11.4941.4941

Published: 2007

Journal Articles

The Utility of Radionuclide Ventriculography (RNV) Prior to Anthracycline Chemotherapy in Patients with Acute Myeloid Leukemia: A Retrospective, Single Institution Study.

Zoe McQuilten, MD, Sharon Avery, MD, Martin Cherk, MD, Stephen S. Opat, MD

Blood (2007) 110 (11): 4369.

https://doi.org/10.1182/blood.V110.11.4369.4369

Published: 2007

Journal Articles

The Clinical Utility of the 1-Deamino-8-D-Arginine Vasopressin (DDAVP) Trial in the Management of Patients with Von Willebrand Disease: A Retrospective Study.

Stephen S. Opat, Jake Shortt, Malgorzata B. Gorniak, Heather A. Aumann, Margaret F. Collecutt, Alison M. Street

Blood (2006) 108 (11): 1033.

https://doi.org/10.1182/blood.V108.11.1033.1033

Published: 2006

Journal Articles

A Novel Fusion of RARA to the PRKAR1A Gene, Encoding the Regulatory Subunit Type-I α of Cyclic AMP Dependent Protein Kinase A, in a Variant Acute Promyelocytic Leukaemia.

Alberto Catalano, BSc, PhD, Mark A. Dawson, BMedSc,MBBS, Karthiga Somana, BSc, Stephen S. Opat, MBBS,FRACP,FRCPA, Lynda J. Campbell, MBBS,FRCPA,FHGSA, Anthony P. Schwarer, MBBS,MD,FRACP,FRCPA, Harry J. Iland, MBBS,FRACP,FRCPA

Blood (2006) 108 (11): 2343.

https://doi.org/10.1182/blood.V108.11.2343.2343

Published: 2006

NARROW

BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101

Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ Trial

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

The Feasibility and Safety of Anticoagulation during Chemotherapy Associated Thrombocytopenia for Thrombotic Complications of Malignancy.

Allogeneic Peripheral Blood Stem Cell Transplantation for Hematological Malignancies in Patients with HIV.

The Utility of Radionuclide Ventriculography (RNV) Prior to Anthracycline Chemotherapy in Patients with Acute Myeloid Leukemia: A Retrospective, Single Institution Study.

The Clinical Utility of the 1-Deamino-8-D-Arginine Vasopressin (DDAVP) Trial in the Management of Patients with Von Willebrand Disease: A Retrospective Study.

A Novel Fusion of RARA to the PRKAR1A Gene, Encoding the Regulatory Subunit Type-I α of Cyclic AMP Dependent Protein Kinase A, in a Variant Acute Promyelocytic Leukaemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only